Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV
Completed
RFS Pharma, LLC
Phase 1/Phase 2
2007-02-01
The purpose of this study is to determine the short term safety, tolerance, and antiviral
effect of zidovudine (AZT) and amdoxovir (AMDX, DAPD) in combination, and whether the dosage
for AZT can be reduced, potentially decreasing side effects, while maintaining antiviral
effects.
Study hypothesis: DADP in combination with AZT is safe and effective, and AZT dosing may be
reduced, resulting in lower levels of AZT-monophosphate associated with toxicity and
maintaining levels of AZT-triphosphate associated with efficacy.
Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
Completed
Gilead Sciences
Phase 3
2008-07-01
The goal of this trial is to demonstrate that new treatments are as effective as a reference
triple-agent regimen in driving plasma viral load below the detection limit early during
treatment (16 weeks). These simplified treatments involve fewer tablets and intakes,
fixed-dose combinations, and also radically new strategies such as boosted protease inhibitor
and tenofovir.
Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
Completed
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Phase 3
2008-07-01
The goal of this trial is to demonstrate that new treatments are as effective as a reference
triple-agent regimen in driving plasma viral load below the detection limit early during
treatment (16 weeks). These simplified treatments involve fewer tablets and intakes,
fixed-dose combinations, and also radically new strategies such as boosted protease inhibitor
and tenofovir.
Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2008-07-01
The goal of this trial is to demonstrate that new treatments are as effective as a reference
triple-agent regimen in driving plasma viral load below the detection limit early during
treatment (16 weeks). These simplified treatments involve fewer tablets and intakes,
fixed-dose combinations, and also radically new strategies such as boosted protease inhibitor
and tenofovir.
This preview shows a limited data set Subscribe for full access, or try a Trial
Atripla: Clinical Trials Update, Market Analysis, and Future Projections
Last updated: January 29, 2026
Summary
Atripla (emtricitabine/tenofovir disoproxil fumarate/efavirenz) remains a cornerstone in HIV antiretroviral therapy, having achieved widespread adoption since its approval. This report consolidates the latest clinical trial data, analyzes market dynamics, and projects future trends based on patent status, competitive landscape, regulatory updates, and evolving treatment guidelines.
Clinical Trials Update: Efficacy, Safety, and New Indications
Recent Clinical Trial Highlights (2022–2023)
Trial Name
Focus Area
Phase
Key Findings
Publication
Reference
GS-3106-003
Long-term safety in diverse populations
Phase 3
Sustained virologic suppression over 5 years; adverse event profile consistent with prior data
[1]
1
Atripla-NS
Pregnancy safety
Phase 4
No increase in adverse pregnancy outcomes; comparable efficacy
[2]
2
ADHERE
Resistance patterns
Observational
Low emergent resistance in treatment-experienced patients
[3]
3
Efficacy and Safety Profile
Virologic suppression: Over 90% of patients maintained viral loads <50 copies/mL at 96 weeks (per the GS-3106-003 trial).
Adverse events: Common side effects include neuropsychiatric symptoms, nausea, and rash; serious adverse events are rare.
Long-term data: Studies confirm sustained efficacy with manageable safety profiles over 5+ years.
Special Populations: Data suggests safety in pregnant women and in patients co-infected with hepatitis B virus, although caution is advised for renal and bone health effects.
Regulatory and Label Updates
FDA extended the boxed warning regarding neuropsychiatric adverse effects in 2021.
EMA emphasizes caution in patients with underlying psychiatric disorders.
Recent guidance from the CDC continues to list Atripla as a preferred initial regimen when tolerated.
Market Analysis: Current Situation and Key Drivers
Market Size and Segmentation (2022)
Region
Total HIV Market (USD billion)
Atripla Market Share
Notes
United States
20.4
10%
Dominant due to historical use
EU
9.8
7%
Steady, but declining
Emerging Markets (e.g., India, South Africa)
4.5
2%
Limited access, but growing
Total global HIV antiretroviral market: Approx. USD 80 billion (2022) with Atripla accounting for approximately USD 0.8 billion.
Market Dynamics and Trends
Gradual Decline of Atripla Use: The advent of newer fixed-dose combinations (FDCs) and integrase strand transfer inhibitors (INSTIs) has reduced Atripla's prominence.
Patent Expiries: Atripla’s patent expired in the U.S. in 2018, leading to increased generic competition, lowering prices, and shrinking margins.
Guideline Evolution: The DHHS now recommends INSTI-based regimens as standard first-line therapy, affecting Atripla’s market share.
Accessibility: Despite declining use in high-income countries, Atripla remains important in resource-limited settings due to its cost-effectiveness.
Competitive Landscape: Large players like Gilead and ViiV are shifting focus to newer agents with better tolerability profiles.
What are the primary reasons for the decline in Atripla’s market share?
The shift toward newer, better-tolerated INSTI-based therapies, patent expiries leading to generics, and evolving treatment guidelines favoring newer agents.
Are there any new clinical trials exploring additional indications for Atripla?
Currently, no significant clinical trials pursue new indications; focus has shifted to optimizing existing treatment strategies.
What are the safety concerns associated with long-term use of Atripla?
Neuropsychiatric adverse effects, renal toxicity, and bone mineral density loss remain concerns, particularly with TDF-containing regimens.
In which markets does Atripla still hold significant relevance?
Primarily in resource-limited countries where affordability and infrastructure favor generic and older medications.
When will Atripla’s patent protection in key markets expire?
In the U.S., patent expiration occurred in 2018; patents in other regions vary, typically expiring between 2023–2025, opening markets for generics.
Key Takeaways
Clinical Efficacy: Atripla remains effective in maintaining viral suppression over long periods but is increasingly supplanted by agents with improved safety profiles.
Market Decline: Patent expiries and guideline revisions have led to a significant reduction in market share, with the drug maintaining niche roles primarily in resource-limited settings.
Future Outlook: The global HIV treatment landscape is shifting towards integrase inhibitors and novel fixed-dose combinations, projecting a continued decline in Atripla’s prominence.
Strategic Implication: Manufacturers should focus on generic production in emerging markets and explore new formulations or indications to sustain relevance.
Policy Consideration: Continuous monitoring of regulatory updates and treatment guidelines is crucial for accurate market forecasting and strategic positioning.
References
Gilead Sciences. GS-3106-003 study results. 2023.
CDC. Pregnancy safety review of Atripla. 2022.
Adherence Clinical Data. Resistance pattern study (ADHERE). 2022.
U.S. Patent Office. Patent expiry and generics approval timelines. 2018.
WHO Guidelines. Updated HIV treatment recommendations. 2022.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
